Tuesday, May 11, 2021

Clinical validation for Avacta’s SARS-CoV-2 antigen lateral flow test

Avacta Group has reported positive data from the clinical validation of its AffiDX SARS-CoV-2 antigen lateral flow test.

Data from the clinical study conducted in Europe on 98 positive COVID-19 samples demonstrate “excellent performance” in identifying the SARS-CoV-2 virus across a broad range of viral loads.

The AIM listed Wetherby-based life science business said this data will now be combined with stability and other performance data from ongoing studies to finalise the technical file for CE marking the AffiDX SARS-CoV-2 antigen lateral flow test for professional use. This will therefore allow the company to begin commercial roll-out in Europe in May.

The clinical evaluation of Avacta’s lateral flow test was carried out at a single site in Europe with patient samples with viral loads confirmed by PCR. The study tested 98 positive samples.

Avacta’s rapid antigen test identified 96/98 of these correctly as positive with a 20 minutes read time resulting in a clinical sensitivity of 98.0% for samples within this broad range down to low viral loads.

Out of a total of 102 negative samples tested with the lateral flow device, the test correctly identified 101 as negative, giving a clinical specificity of 99.0%.

“I am delighted with the clinical data from this larger clinical study, which has robustly evaluated the AffiDX antigen test with lower viral loads of Ct>26 as well as with higher viral load samples. The results are very impressive and marks a major step in obtaining a CE mark for professional use,” said Dr Alastair Smith, Chief Executive of Avacta Group.

“As part of the study the same clinical samples were tested with two leading, commercially available lateral flow antigen tests, and the data show that the AffiDX test had better clinical sensitivity across the range of Ct value and in particular at lower viral loads.

“We are completing the necessary assessment of the product from our manufacturing partner Global Access Diagnostics, including stability testing that will complete the technical file for CE marking, which we expect will happen in early May.

“We are very excited by the potential of this high quality SARS-CoV-2 rapid antigen test and we are looking forward to updating the market as we commercially roll-out the AffiDX® test in the coming months.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site and magazine but journalism costs money and we rely on advertising, print and digital revenues to help to support them.

With the Covid-19 pandemichaving a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites/magazines with either a small donation of even £1, or a subscription to our magazine, which costs just £31.50 per year, (inc p&P and mailed direct to your door) your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

As a subscriber, you will have unlimited access to our web site and magazine. You'll also be offered VIP invitations to our events, preferential rates to all our awards and get access to exclusive newsletters and content.

Just click here to subscribe and in the meantime may I wish you the very best.




Latest news

Builder shortage? 3 tips for improving recruitment

Standards are high in the construction field, so it’s important that your recruitment processes are impeccable. This will help you net the best talent on...

How a bad job advert can affect your chances of finding the right candidate

A job advert is your first opportunity to introduce yourself to prospective employees and attract the right talent. It is crucial this first impression...

Britain’s bosses accused of negligence: what might they do to improve?

Due to the difficult conditions most businesses are subject to, the need for apt leadership is perhaps more prevalent than ever before. A damning BBC...

Lincoln Science Park secures £10m to accelerate second phase of development

A £10m funding package has been secured to begin developing the next stage of Lincoln Science & Innovation Park. This follows its success in...

Sheffield solicitors launch national wealth service

Sheffield solicitors, Taylor&Emmet, is introducing a new multidisciplinary service tailored to the needs of high-net-worth and ultra-high-net-worth individuals. The firm has created a dedicated wealth...

Developer secures £17m to improve South Leeds’ transport infrastructure

Leeds property investment and development company, Munroe K, has secured £17 million to improve transport infrastructure in South Leeds. The company secured the funds after...

Related news

Builder shortage? 3 tips for improving recruitment

Standards are high in the construction field, so it’s important that your recruitment processes are impeccable. This will help you net the best talent on...

How a bad job advert can affect your chances of finding the right candidate

A job advert is your first opportunity to introduce yourself to prospective employees and attract the right talent. It is crucial this first impression...

Britain’s bosses accused of negligence: what might they do to improve?

Due to the difficult conditions most businesses are subject to, the need for apt leadership is perhaps more prevalent than ever before. A damning BBC...

Lincoln Science Park secures £10m to accelerate second phase of development

A £10m funding package has been secured to begin developing the next stage of Lincoln Science & Innovation Park. This follows its success in...

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close